Section 4: Clinical Pharmacy Services

4CPS-090​

EFFICACY AND SAFETY OF PANGENOTYPS TREATMENTS IN HCV PATIENTS

4CPS-087

THE USE OF PATIENT-REPORTED OUTCOME INSTRUMENTS IN IMMUNE CHECKPOINT INHIBITOR THERAPY FOR CANCER IN CLINICAL PRACTICE: A SYSTEMATIC REVIEW

4CPS-075

EVALUATION OF THE COST OF MANAGING ADVERSE EVENTS RELATED TO CYTOTOXIC DRUGS IN CHILDREN

4CPS-072

BEZLOTOXUMAB FOR THE PREVENTION OF CLOSTRIDIOIDES DIFFICILE RECURRENCE: STUDY IN THE REAL WORLD

4CPS-071

CYP27B1 GENETIC VARIANTS’ INFLUENCE IN NEPHROTOXICITY DUE TO PLATINUMBASED CHEMOTHERAPY IN NON-SMALL CELL LUNG CANCER

4CPS-069

INFLUENCE OF GENETIC VARIANTS IN THE VITAMIN D HYDROXYLATION PATHWAY AS A RESPONSE FACTOR TO PLATINUM-BASED CHEMOTHERAPY IN NONSMALL CELL LUNG CANCER

4CPS-067

PHARMACIST INTERVENTIONS IN SEQUENTIAL ANTIMICROBIAL THERAPY INSIDE AN ANTIMICROBIAL STEWARDSHIP PROGRAMME (ASP)

4CPS-063

ERENUMAB VERSUS GALCANEZUMAB, EFFECTIVENESS IN REAL-LIFE EXPERIENCE

4CPS-061​

IMPACT OF PHARMACOGENETICS ON THE TOXICITY OF HIGH-DOSE METHOTREXATE IN A PAEDIATRIC POPULATION

4CPS-060​

INFLUENCE OF GENETIC POLYMORPHISMS ON THE RESPONSE AND TOXICITY OF CAPECITABINE THERAPY IN PATIENTS WITH BREAST CANCER

4CPS-057

DISCONTINUATION OF PROTON PUMP INHIBITORS DURING HOSPITALISATION: A RANDOMISED CONTROLLED TRIAL

4CPS-054

ANALYSIS OF REAL-WORLD DATA FOR ERENUMAB UTILISATION AND PATIENT-RELATED OUTCOMES

4CPS-051

PHARMACOKINETICS ALTERATIONS IN TWO CRITICALLY ILL PATIENTS ON EXTRACORPOREAL MEMBRANE OXYGENATION RECEIVING ISAVUCONAZOL

4CPS-038

Intrapleural colistin for pleural empyema caused by extensively drug-resistant Pseudomonas aeruginosa: A case report

4CPS-035

PHARMACIST-LED MEDICATION RECONCILIATION AT DISCHARGE SHALL NOT BE SUFFICIENT TO REDUCE UNPLANNED HEALTHCARE UTILIZATION: HEAR THE PATIENT EXPERIENCE!

Pages